SGLT2 Inhibitors in T2DM Linked to Lower GI Cancer Risk SGLT2 Inhibitors in T2DM Linked to Lower GI Cancer Risk
Researchers used a large national database to compare risk of all types of GI cancers associated with popular drug classes used to treat type 2 diabetes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news
More News: Cancer | Cancer & Oncology | Databases & Libraries | Diabetes | Diabetes Type 2 | Endocrinology | Gastroenterology | Health | SGLT2 Inhibitors